"Primary Myelofibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.
| Descriptor ID |
D055728
|
| MeSH Number(s) |
C15.378.190.636.765
|
| Concept/Terms |
Primary Myelofibrosis- Primary Myelofibrosis
- Myelofibroses, Primary
- Myelofibrosis, Primary
- Primary Myelofibroses
- Bone Marrow Fibrosis
- Bone Marrow Fibroses
- Fibroses, Bone Marrow
- Fibrosis, Bone Marrow
- Myelofibrosis
- Myelofibroses
- Idiopathic Myelofibrosis
- Myeloid Metaplasia
- Metaplasia, Myeloid
- Metaplasias, Myeloid
- Myeloid Metaplasias
- Myelosclerosis
- Myeloscleroses
- Myelosis, Nonleukemic
- Myeloses, Nonleukemic
- Nonleukemic Myeloses
- Nonleukemic Myelosis
- Chronic Idiopathic Myelofibrosis
- Agnogenic Myeloid Metaplasia
- Agnogenic Myeloid Metaplasias
- Metaplasia, Agnogenic Myeloid
- Metaplasias, Agnogenic Myeloid
- Myeloid Metaplasia, Agnogenic
- Myeloid Metaplasias, Agnogenic
- Myelofibrosis With Myeloid Metaplasia
|
Below are MeSH descriptors whose meaning is more general than "Primary Myelofibrosis".
Below are MeSH descriptors whose meaning is more specific than "Primary Myelofibrosis".
This graph shows the total number of publications written about "Primary Myelofibrosis" by people in this website by year, and whether "Primary Myelofibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 2 | 1 | 3 |
| 2003 | 0 | 1 | 1 |
| 2004 | 4 | 1 | 5 |
| 2005 | 8 | 3 | 11 |
| 2006 | 7 | 0 | 7 |
| 2007 | 9 | 2 | 11 |
| 2008 | 6 | 1 | 7 |
| 2009 | 10 | 2 | 12 |
| 2010 | 10 | 0 | 10 |
| 2011 | 6 | 1 | 7 |
| 2012 | 15 | 0 | 15 |
| 2013 | 26 | 5 | 31 |
| 2014 | 14 | 0 | 14 |
| 2015 | 29 | 1 | 30 |
| 2016 | 21 | 3 | 24 |
| 2017 | 22 | 2 | 24 |
| 2018 | 16 | 2 | 18 |
| 2019 | 13 | 0 | 13 |
| 2020 | 20 | 0 | 20 |
| 2021 | 16 | 0 | 16 |
| 2022 | 31 | 0 | 31 |
| 2023 | 28 | 0 | 28 |
| 2024 | 19 | 1 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Primary Myelofibrosis" by people in Profiles.
-
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. J Hematol Oncol. 2024 Nov 15; 17(1):112.
-
Proposals for revised International Working Group-European LeukemiaNet criteria for anemia response in myelofibrosis. Blood. 2024 10 24; 144(17):1813-1820.
-
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care? Expert Rev Hematol. 2024 Nov; 17(11):769-780.
-
Safety and efficacy of luspatercept for the treatment of anemia in?patients with myelofibrosis. Blood Adv. 2024 09 10; 8(17):4511-4522.
-
Donor types and outcomes of transplantation in myelofibrosis: a?CIBMTR study. Blood Adv. 2024 08 27; 8(16):4281-4293.
-
Momelotinib for the treatment of myelofibrosis. Blood. 2024 08 15; 144(7):708-713.
-
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study. Haematologica. 2024 08 01; 109(8):2660-2664.
-
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature. Expert Opin Pharmacother. 2024 Jul; 25(10):1391-1404.
-
Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM. Future Oncol. 2024; 20(30):2259-2270.
-
Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database. Ann Hematol. 2024 Sep; 103(9):3543-3551.